Navigation Links
PCMA Outlines $100 Billion in Prescription Drug Savings for Deficit Reduction Committee

WASHINGTON, Aug. 31, 2011 /PRNewswire-USNewswire/ -- As the Joint Select Committee on Deficit Reduction examines options to reduce the deficit by $1.5 trillion over the next ten years, the Pharmaceutical Care Management Association (PCMA) outlined in a letter to the committee opportunities to leverage greater use of pharmacy benefit management tools to save more than $100 billion in prescription drug costs over that same time period.

"Everyone in the pharmacy community: drugstores, pharmacy benefit managers, drug companies, drug wholesalers, and others have a responsibility to offer cost-saving solutions to this committee," said PCMA President and CEO Mark Merritt. "The solutions we outline would save more than $100 billion, improve prescription drug benefits, and increase access to these benefits."

Using innovative cost-saving tools and technologies, PBMs have worked closely with payers in designing drug benefits that lower costs and expand access to prescription drugs.  These tools – including pharmacy networks, home delivery, utilization management (such as step therapy and prior authorization), and formularies – help make prescription drug benefits more affordable.

Below are options PCMA recommended to the Joint Select Committee:

  • Modernize Medicaid Pharmacy. Over the next decade, the federal government could save $21 billion – without cutting benefits or payments to doctors and hospitals – by modernizing Medicaid pharmacy benefits. Currently, the program uses fewer generic drugs and pays drugstores more than double the dispensing fees that Medicare or private insurers pay.
  • Maximize Generic and Therapeutic Substitution in Part D.  Fully realize the potential savings available as outlined by the Congressional Budget Office to increase generic and therapeutic interchange opportunities in Part D by shifting spending from the most expensive single source drugs to equally effective lower cost options.
  • Expedite the Approval of Biogenerics.  Increase competition for biologic drugs by reducing the number of years a drug company has "exclusivity" or monopoly pricing power.   As the number and costs of these expensive biologic drugs drastically increases, so does the urgency to begin the approval pathway for biogenerics as quickly as possible.  
  • Allow Part D Plans to Negotiate Greater Discounts on All Drugs.  Increase price competition among brand drug manufacturers by removing the mandate that "all or substantially all" drugs in six protected classes be covered.  Manufacturers with a guarantee that their drug is covered have no incentive to offer a discount to Part D plans or beneficiaries.
  • Ban a Tax Deduction for Direct-to-Consumer (DTC) Drug Advertising.  DTC drug advertising is a key tool used by brand drug manufacturers to drive consumers to take brand medications and the costs of this advertising are tax deductible.  While the First Amendment allows for such advertising, it does not require tax payers to subsidize promoting the most expensive drug treatments.
  • Encourage Chronic Care Pharmacy and Home Delivery.  Currently, due to restrictions in Medicare Part D, beneficiaries in private-sector retiree plans use home delivery four times more often than those in Part D plans.  Home delivery is popular with patients because it offers less expensive 90-day prescriptions and is more convenient than driving to the drugstore.  With mail-service pharmacies, patients can get private counseling over the phone from trained pharmacists seven days a week, 24 hours a day.  Removing Medicare's restrictions on home delivery and encouraging beneficiaries to get their maintenance medications by mail could improve drug adherence and save Medicare hospital and physician costs.
  • Ban Pay-for-Delay Drug Settlements.  Currently, brand drug companies are making deals with generics to delay offering a competing generic, allowing the more expensive brand drug to stay on the market for a longer period of time, resulting in higher costs.  Prohibiting pay-for-delay agreements would facilitate quicker access to lower-cost generics.

PCMA represents the nation's pharmacy benefit managers (PBMs), which improve affordability and quality of care through the use of electronic prescribing (e-prescribing), generic alternatives, mail-service pharmacies, and other innovative tools for 200-plus million Americans.

SOURCE Pharmaceutical Care Management Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Outlines Oversight of Mobile Medical Applications
2. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
3. Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements
4. Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
5. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
6. Medical Affairs Report Outlines Resource Needs for Group Success
7. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
8. Solos Endoscopy, Inc. Outlines Marketing Strategy for 2010 Campaign
9. Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
10. Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes
11. Bob McDonald Outlines Key Long Term Growth Strategies To P&G Shareholders
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Hanger, Inc. (NYSE: ... restatement of the terms of its previously announced consent ... to its $200,000,000 aggregate principal amount 7⅛% Senior Notes ... (i) the consent fees payable pursuant to the Consent ... Notes and (iii) the expiration date of the Consent ...
(Date:11/30/2015)...  Precision Image Analysis Inc. (PIA), a leading ... a dramatic expansion of its capabilities as a ... ISO-9001:2008 certification for its Quality Management System, PIA ... and procedures. This expansion enables PIA to support ... Lab services include design and optimization of protocols, ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. 30, ... company focused on acquiring and developing innovative therapies for ... appointment of Keith A. Katkin as chairman ... J. Flesher , chief executive officer for OticPharma, Ltd.  ... organizations.  As chairman, he will be able to share ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (ASI) as their exclusive channel partner for the Nutraceutical Specialties products into oral ... the US, effective immediately. , “We are pleased to announce our expanded ...
(Date:11/30/2015)... ... 2015 , ... Medicalis, a leading developer of enterprise-scale Imaging ... (RSNA) annual meeting, being held November 29 – December 3, 2015, that its ... company has completed installations for Integrated Delivery Network (IDN) customers such as WellSpan, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and ... Mesh technology for soft tissue repair in the US via Insightra’s national direct ... surgical mesh intended to support and reinforce soft tissue for 6-9 months before ...
(Date:11/30/2015)... ... ... TransPack Volume 6 features 30 customizable transitions created exclusively for use within ... with blur & drop shadow options. Utilize the controls in the inspector window ... the next with TransPack's easily customizable styles. , TransPack Volume 6 features ...
Breaking Medicine News(10 mins):